Sitagliptin Tecnimed 50 mg film-coated tablets EFG

Spain
Brand name Sitagliptin Tecnimed 50 mg film-coated tablets EFG
Form tablets, film-coated
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 89262
Sitagliptin Tecnimed 50 mg film-coated tablets EFG tablets, film-coated

Patient Information Leaflet

Introduction

Stylized dark blue logo composed of two mirrored curved shapes with a heraldic coat of arms above and Spanish text at the bottom of the page

Patient Information Leaflet

Sitagliptin Tecnimede 50 mg film-coated tablets EFG

Read the entire leaflet carefully before starting to take this medicine, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you personally and must not be given to others, even if they have the same symptoms as you, as it could harm them.
  • If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if the effects are not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What Sitagliptina Tecnimede is and what it is used for
  2. What you need to know before starting to take Sitagliptina Tecnimede
  3. How to take Sitagliptina Tecnimede
  4. Possible side effects
  5. Storage of Sitagliptina Tecnimede
  6. Contents of the pack and additional information

1. What is Sitagliptina Tecnmede and what is it used for?

This medicine contains the active substance sitagliptin, which belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that reduce blood sugar levels in adult patients with type 2 diabetes mellitus.

This medicine helps increase insulin levels produced after a meal and decreases the amount of sugar produced by the body.

Your doctor has prescribed this medicine to help you lower your blood sugar, which is too high due to your type 2 diabetes. This medicine may be used alone or in combination with other blood sugar-lowering medicines (such as insulin, metformin, sulfonylureas, or glitazones) that you may already be taking for your diabetes, along with a diet and exercise program.

What is type 2 diabetes?

Type 2 diabetes is a condition in which your body does not produce enough insulin, and the insulin it does produce does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart disease, kidney disease, blindness, and amputation.

Stylized logo of the Spanish Ministry of Health with royal coat of arms above the acronym MM on a white background

2. What you need to know before starting to take Sitagliptin Tecnimede

Do not take Sitagliptin Tecnimede

  • if you are allergic to sitagliptin or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Cases of inflammation of the pancreas (pancreatitis) have been reported in patients treated with sitagliptin (see section 4).

If you notice blisters on the skin, this may be a sign of a condition called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin.

Inform your doctor if you have or have had:

  • a pancreatic disease (such as pancreatitis)
  • gallstones, alcohol addiction, or very high blood levels of triglycerides (a type of fat). These medical conditions may increase your likelihood of developing pancreatitis (see section 4)
  • type 1 diabetes
  • diabetic ketoacidosis (a diabetes complication causing high blood sugar levels, rapid weight loss, nausea or vomiting)
  • any kidney problems currently or in the past
  • an allergic reaction to sitagliptin (see section 4).

It is unlikely that this medicine will cause low blood sugar because it does not act when blood sugar levels are low. However, when this medicine is used in combination with a medicine containing a sulfonylurea or with insulin, low blood sugar (hypoglycemia) may occur. Your doctor may reduce the dose of your medicine containing sulfonylurea or insulin.

Children and adolescents

Children and adolescents under 18 years of age should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is unknown whether this medicine is safe and effective when used in children under 10 years of age.

Other Medicines and Sitagliptina Tecnimede

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

In particular, inform your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and other heart problems). It may be necessary to monitor your digoxine blood levels if you are taking sitagliptina.

Taking Sitagliptina Tecnimede with food and drinks
You may take this medicine with or without food and drinks.

Pregnancy, lactation and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine. This medicine should not be taken during pregnancy.

It is unknown whether this medicine passes into breast milk. You should not take this medicine if you are breastfeeding or plan to breastfeed.

Stylized logo of the Spanish Ministry of Health with a heraldic coat of arms above the acronym MM in black on a white background

Driving and operating machinery

The influence of this medicine on the ability to drive or operate machinery is none or negligible. However, dizziness and somnolence have been reported, which may affect your ability to drive or operate machinery.

Likewise, taking this medicine together with medications called sulfonamides or with insulin may cause hypoglycemia, which could impair your ability to drive and operate machinery or work without secure support.

SitagliptinTecnimede contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; that is, essentially "sodium-free".

3. How to take Sitagliptin Tecnimede

Follow exactly the instructions for use of this medicine given by your doctor. If in doubt, consult your doctor or pharmacist again.

The usual recommended dose is:

  • one 100 mg film-coated tablet
  • once daily
  • taken orally.

If you have kidney problems, your doctor may prescribe you lower doses (such as 25 mg or 50 mg).

You may take this medicine with or without food and beverages.

Your doctor may prescribe this medicine alone or together with other medicines that also lower blood sugar. Diet and exercise can help the body use sugar more effectively. It is important to follow the diet and exercise regimen recommended by your doctor while taking sitagliptin.

If you take more Sitomamas Sitagliptin Tecnimede than you should

If you take more doses of this medicine than prescribed, contact your doctor immediately.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicology Information Service at telephone number: 91 562 04 20, indicating the medication and the amount ingested.

If you forget to take Sitagliptin Tecnimede

If you forget a dose, take it as soon as you remember. If you do not remember until it is time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose of this medication.

If you stop treatment with Sitagliptin Tecnimede

Keep taking this medication for as long as your doctor prescribes it, so it can continue helping you control your blood sugar. You should not stop taking this medicine without first consulting your doctor.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

Stylized logo of the Spanish Ministry of Health composed of two mirrored curved shapes above a heraldic coat of arms with text below

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

STOP taking Sitagliptin Tecnimede and contact your doctor immediately if you notice any of the following serious adverse effects:

  • Severe and persistent pain in the abdomen (stomach area) that may extend to the back, with or without nausea and vomiting, as these may be signs of inflammation of the pancreas (pancreatitis).

If you have a severe allergic reaction (frequency not known), including skin rash, hives, skin blisters/skin peeling, and swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing, stop taking this medicine and contact your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and will switch your diabetes treatment to another medicine.

Some patients experienced the following adverse effects after adding sitagliptin to metformin treatment:

Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting

Uncommon (may affect up to 1 in 100 people): stomach pain, diarrhoea, constipation, somnolence.

Some patients experienced various types of stomach discomfort when starting treatment with sitagliptin and metformin together (frequency classified as common).

Some patients experienced the following adverse effects while taking sitagliptin in combination with a sulphonylurea and metformin:

Very common (may affect more than 1 in 10 people): low blood sugar

Common: constipation

Some patients experienced the following adverse effects while taking sitagliptin and pioglitazone:

Common: flatulence, swelling of hands or legs

Some patients experienced the following adverse effects while taking sitagliptin in combination with pioglitazone and metformin:

Common: swelling of hands or legs

Some patients experienced the following adverse effects while taking sitagliptin in combination with insulin (with or without metformin):

Common: influenza-like illness

Uncommon: dry mouth

Some patients experienced the following adverse effects while taking sitagliptin alone during clinical trials, or during post-marketing use alone and/or in combination with other antidiabetic medicines:

Common: low blood sugar, headache, upper respiratory tract infection, nasal congestion or runny nose, sore throat, osteoarthritis, arm or leg pain

Uncommon: dizziness, constipation, itching

Rare: reduction in platelet count

Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)

Stylized logo of the Spanish Ministry of Health with a heraldic coat of arms above the acronym MM on a white background

Reporting suspected adverse reactions

It is important to report suspected adverse reactions to the medicine after authorisation. This enables continued monitoring of the benefit-risk balance of the medicine. Healthcare professionals are encouraged to report suspected adverse reactions via the

Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es.

5. Storage of Sitagliptin Tecnimede

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister pack and on the outer packaging after CAD/EXP. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines must not be disposed of via wastewater drains or household waste. Unused medicines and their containers should be taken to the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of medicines and containers you no longer need. This will help protect the environment.

Stylized logo of the Spanish Ministry of Health with a heraldic coat of arms above the acronym MM on a white background

6. Contents of the pack and other information

Composition of Sitagliptin Tecnimede

The active substance is sitagliptin.

Each film-coated tablet contains sitagliptine hydrochloride monohydrate equivalent to 50 mg of sitagliptin.

The other components are:

In the tablet core: microcrystalline cellulose (E 460), calcium hydrogen phosphate, sodium starch glycolate (E 468), colloidal anhydrous silica, stearoyl fumarate and sodium, magnesium stearate (E470b).

The tablet coating contains: poly (vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), yellow iron oxide (E172), red iron oxide (E172).

Appearance of the product and contents of the container

Pale beige, round, film-coated tablets, engraved with "S" on one sideStylized dark blue logo composed of two mirrored curved shapes with a heraldic coat of arms above and text below on a white background.

Sitagliptin Tecnimede is available in opaque blisters (PVC/PE/PVDC and aluminum). Pack sizes of 10, 28, 30, 60 and 98 film-coated tablets.

Only some pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Tecnimede España Industria Farmacéutica S.A.

Avda. de Bruselas, 13, 3º D.

28108 Alcobendas (Madrid)

Spain

Manufacturer

SAG MANUFACTURING, S.L.U.

Ctra. N-I, Km 36. 28750 San Agustin de Guadalix, Madrid (Spain)

GALENICUM HEALTH, S.L.U

Sant Gabriel, 50

Esplugues de Llobregat, 08950

Barcelona, Spain

Stylized logo of the Spanish Ministry of Health with coat of arms and acronym at the top and informational text at the bottom on a white background

Date of the most recent review of this leaflet: November 2023

Detailed information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/